Editorial comment

Urology. 2010 Jun;75(6):1458. doi: 10.1016/j.urology.2009.10.071.
No abstract available

Publication types

  • Comment
  • Comparative Study
  • Editorial

MeSH terms

  • Carbolines / therapeutic use
  • Dose-Response Relationship, Drug
  • Erectile Dysfunction / complications
  • Erectile Dysfunction / diagnosis
  • Erectile Dysfunction / drug therapy
  • Humans
  • Male
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Prostatic Hyperplasia / complications
  • Prostatic Hyperplasia / diagnosis
  • Prostatic Hyperplasia / drug therapy*
  • Prostatism / complications
  • Prostatism / diagnosis
  • Prostatism / drug therapy*
  • Quality of Life
  • Risk Assessment
  • Tadalafil
  • Treatment Outcome
  • Urination Disorders / complications
  • Urination Disorders / diagnosis
  • Urination Disorders / drug therapy*

Substances

  • Carbolines
  • Phosphodiesterase Inhibitors
  • Tadalafil